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Miscellaneous Disorders of Calcium and Bone Metabohsm 
Gregory R. Mundy, MD* 
Pathophysiology of Hypercalcemia 
During this section of the meeting a miscellaneous group of disorders affecting calcium homeostasis and bone metabo-
lism were reviewed by investigators with special experience 
with these particular disorders. Kanis et al (1) discussed the dis-
tribution of calcium in normal plasma, the importance of bind-
ing to plasma proteins, and the effects that this has on interpreta-
tion of measurements of total plasma calcium. They discussed 
the transport of calcium between the extracellular fluid and the 
gut, bone, and the kidney and stressed the importance of the 
kidney and in particular renal tubular calcium reabsorption 
in calcium homeostasis. They then reviewed how careful de-
termination of urine calcium excretion may give insight into 
calcium fluxes from the skeleton and calcium absorption from 
the gut. 
Hypercalcemia: Solid Thmors 
One of the commonest causes of hypercalcemia is malignant 
disease. Kanis et al (1) indicated that hypercalcemia occurs in 
malignant disease in a number of different settings. Martin (2) 
discussed a newly described factor associated with one of these 
settings, namely the humoral hypercalcemia of malignancy. In 
this syndrome, a solid tumor produces a humoral factor which 
alone or in concert with other factors stimulates osteoclastic 
bone resorption, enhances renal tubular calcium reabsorption, 
and increases urinary cyclic AMP. Martin described a biological 
activity from one of these tumors which stimulated adenylate 
cyclase activity in bone cells and in renal membranes, whose 
effects were blocked by synthetic antagonists to parathyroid hor-
mone (PTH) and which was not affected by antisera to PTH. He 
described the purification and molecular cloning of this factor 
and the biological effects of synthetic fragments. This factor, 
which was referred to as the PTH-related protein, has consider-
able homology to authentic parathyroid hormone in the N-termi-
nal region since eight of the first 13 amino acids are identical. It 
binds to the PTH receptor and activates it. It stimulates bone re-
sorption and renal tubular calcium reabsorption and increases 
plasma calcium in vivo. Immunoreactive PTH-rP was found in a 
variety of tumors, some of which are associated with hyper-
calcemia and some of which are not. 
eloma, hypercalcemia occurs as a consequence of increased 
bone resorption usually associated with decreased glomemlar 
filtration. In this malignancy, the tumor cells produce a cytokine 
(lymphotoxin) which stimulates osteoclastic bone resorption in 
vitro and in vivo and increases plasma calcium in vivo. In some 
lymphomas associated with hypercalcemia, there is increased 
production of 1,25-dihydroxyvitamin D. This has been found in 
association with adult T-cell lymphomas, with B-cell lympho-
mas, and in occasional cases with Hodgkin disease. It seems 
likely in these circumstances that the neoplastic lymphoid cells 
have developed the capacity to synthesize 1,25-dihydroxy-
vitamin D. 
Paget Disease of Bone: Assessment, Therapy, and 
Secondary Prevention 
Bijvoet et al (4) gave an update of Paget disease of bone. This 
bone disorder is characterized by a primary abnormality in the 
osteoclast which is accompanied by morphologic abnormalities 
which include increased multinucleation, increased functional 
capacity, and the presence of intranuclear inclusion bodies. 
These intranuclear inclusion bodies seem likely to be due to a 
slow vims which is probably the primary cause of this disorder. 
Paget disease which is associated with pain or deformity can be 
treated with calcitonin or with one of the dmgs of the bipbospho-
nate family. Bijvoet et al stressed the utility of the newer bi-
phosphonates, particularly the amino biphosphonates, which 
are more potent than the first-generation agents, produce fewer 
side effects, and may lead to better and more prolonged 
therapeutic responses. 
Renal Calculi: Update 
Pak (5) discussed the current status of pathophysiology, diag-
nosis, and medical management of renal calculi. He reviewed 
the history of the pathophysiologic approach to diagnosis and 
treatment of recurrent renal calculi. He discussed the three 
major mechanisms thought responsible for hypercalciuria— 
Mechanisms of Hypercalcemia in 
Hematologic Malignancies 
Factors which are implicated in the hypercalcemia associated 
with hematologic malignancies were described (3). In my-
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absorptive hypercalciuria, resorptive hypercalciuria, and renal 
leak hypercalciuria—and reported on other less common mech-
anisms including the primary renal phosphate leak group, the 
group associated with primary enhancement of 1,25 D produc-
tion, and the group with combined renal tubular disturbances 
which lead to hypercalciuria. Pak reviewed the role of hypo-
citmria which is present in 70% to 80% of patients with recur-
rent renal calculi and hypercalciuria. Hypocitmria has multiple 
causes, is easily diagnosed, and readily corrected by potassium 
citrate, an effective dmg which reduces stone formation in these 
patients. In discussing the utility of medical prevention of recur-
rent renal calculi with the use of thiazides and potassium citrate, 
he suggested that despite the recent striking advances in the sur-
gical approach to recurrent renal stones, medical therapy had a 
useful place in prevention of further development of stones, re-
duction of the need for further surgery, and as a cost-effective 
form of therapy. However, he stressed that medical therapy does 
not cure the underlying defect responsible for this disorder 
which still requires diagnostic evaluation for careful choice 
of therapy. 
Current Problems in Renal Osteodystrophy 
Recent concepts of the pathophysiology of renal bone disease 
were discussed by Boyce et al (6). Renal bone disease is com-
prised of three main pathologic entities: osteitis fibrosa (second-
ary hyperparathyroidism), osteomalacia responsive to vitamin 
D metabolites, and aluminum bone disease. Boyce et al showed 
that aluminum is an important pathophysiologic agent in bone 
disease associated with chronic renal disease and is responsible 
for a syndrome characterized by resistance to therapy with 1,25-
dihydroxyvitamin D, a relative decrease in semm immunoreac-
tive parathyroid hormone, a relative decrease in alkaline phos-
phatase, and the bone biopsy picture of osteomalacia. There are 
several variants to the bone biopsy picture. These include pure 
osteomalacia with low mineralization rates, thick osteoid seams 
and no evidence of osteitis fibrosa, a mixed picture of osteo-
malacia and osteitis fibrosa, and an aplastic or adynamic biopsy 
appearance associated with low bone tumover. They pointed out 
that patients who are particularly at risk for aluminum intoxica-
tion were those who were hyperabsorbers of aluminum, those 
who used dialysis water in which aluminum was not removed by 
treatment of water with reverse osmosis or deionization, and 
those who ingest large amounts of aluminum binders. They then 
reviewed the difficulties in diagnosis of aluminum bone disease 
without a bone biopsy. This can be made with the desferriox-
amine test followed by measurement of the semm aluminum re-
sponse, although this test is not uniformly reliable. They indi-
cated the potential problems of patients with aluminum bone 
disease who were subjected to parathyroidectomy and con-
cluded by indicating that hypercalcemia in a patient with chronic 
renal disease should not be treated by parathyroidectomy unless 
aluminum bone disease has been carefully excluded, that alumi-
num toxicity is still an important cause of renal bone disease, 
and that the role of parathyroidectomy in exacerbating alumi-
num bone disease in a patient with underlying increased alumi-
num content in bone remains unclear. 
The Pathogenesis and Clinical Course of Multiple 
Endocrine Neoplasia l^pe 2A 
The session concluded with a review of the multiple endo-
crine neoplasia type 2A (MEN-2A) syndrome by Gagel (7). 
This syndrome comprises medullary thyroid carcinoma, pheo-
chromocytoma, and parathyroid hyperplasia. It was first de-
scribed by Sipple in 1961. Gagel showed how this syndrome has 
gone through three phases beginning with the clinical descrip-
tion in the 1960s, followed by the use of calcitonin measurement 
in the diagnosis and screening of asymptomatic patients in the 
1970s, and then by recent advances in understanding the abnor-
malities in gene function which lead to the molecular derange-
ments in patients with this syndrome. He pointed out that the 
thyroid disease almost always occurs first and that the adrenal 
disease is a particularly difficult problem because it is frequently 
diffuse and bilateral. However, the adrenal tumors are rarely 
malignant, are almost always intraadrenal, and usually secrete 
epinephrine. His preference is that a patient with evidence for 
disease in only one adrenal should undergo unilateral adre-
nalectomy initially. Thyroidectomy should be performed on in-
dividuals with abnormalities in calcitonin secretion at the ear-
liest feasible time. Recently, the gene responsible for this disor-
der has been mapped to chromosome 10 at a point near the 
centromere. It appears most likely that oncogenesis in this disor-
der is due to a deletion of a regulatory gene similar to that which 
has been described in patients with retinoblastoma. In 
MEN-2A, this deletional mutation is present near the cen-
tromere of chromosome 10. It is hoped that these studies will 
lead soon to the ability to diagnose this disease at birth which 
may lead to changes in the therapeutic approach (particularly 
with respect to timing of thyroidectomy) and an improvement in 
the overall prognosis. At the present time, in patients who are 
screened and diagnosed as having underlying thyroid disease 
before the onset of symptoms, about 90% are disease-free at five 
years if they are subjected to total thyroidectomy. 
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